Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Medical Office Denmark ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.7% 0.7%   Bankruptcy risk   1.8% 1.7% 5.5% 1.6% 1.8% 2.4% 17.2% 17.0%   Credit score (0-100)   73 75 41 73 71 63 9 10   Credit rating   A A BBB A A BBB BB BB   Credit limit (kDKK)   1.2 3.7 0.0 9.5 1.5 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   4,133 4,137 2,894 6,305 5,028 4,441 0.0 0.0   EBITDA   834 965 -200 2,126 741 532 0.0 0.0   EBIT   621 749 -415 1,916 520 494 0.0 0.0   Pre-tax profit (PTP)   575.6 705.8 -453.6 1,864.1 426.0 430.0 0.0 0.0   Net earnings   448.0 549.5 -349.7 1,806.0 348.4 344.5 0.0 0.0   Pre-tax profit without non-rec. items   576 706 -454 1,864 426 430 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   145 112 75.7 130 162 148 0.0 0.0   Shareholders equity total   1,142 1,441 592 2,398 1,146 791 241 241   Interest-bearing liabilities   26.8 68.9 18.2 74.6 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,197 2,458 2,049 4,413 1,951 1,591 241 241   Net Debt   -804 -1,419 -980 -1,554 -20.3 -46.7 -241 -241     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   4,133 4,137 2,894 6,305 5,028 4,441 0.0 0.0   Gross profit growth   33.6% 0.1% -30.0% 117.9% -20.3% -11.7% -100.0% 0.0%   Employees   4 4 0 5 5 4 0 0   Employee growth %   0.0% 0.0% -100.0% 0.0% 0.0% -20.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,197 2,458 2,049 4,413 1,951 1,591 241 241   Balance sheet change%   48.6% 11.9% -16.6% 115.4% -55.8% -18.5% -84.9% 0.0%   Added value   834.1 965.4 -199.8 2,126.4 730.0 531.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -371 -421 -423 -327 -361 -51 -148 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 2.0 -1.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   15.0% 18.1% -14.3% 30.4% 10.3% 11.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   33.8% 32.2% -18.4% 59.4% 16.3% 28.6% 0.0% 0.0%   ROI %   66.3% 54.1% -37.7% 124.4% 28.7% 52.3% 0.0% 0.0%   ROE %   48.8% 42.5% -34.4% 120.8% 19.7% 35.6% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   52.0% 58.6% 28.9% 54.3% 58.7% 49.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -96.4% -147.0% 490.2% -73.1% -2.7% -8.8% 0.0% 0.0%   Gearing %   2.3% 4.8% 3.1% 3.1% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   292.2% 89.4% 88.6% 115.3% 251.7% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.2 1.9 1.1 1.7 2.1 1.7 0.0 0.0   Current Ratio   1.3 2.0 1.1 2.0 2.2 1.8 0.0 0.0   Cash and cash equivalent   831.2 1,488.0 997.9 1,628.2 20.3 46.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   316.5 899.2 173.3 2,096.6 984.6 642.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   209 241 0 425 146 133 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   209 241 0 425 148 133 0 0   EBIT / employee   155 187 0 383 104 123 0 0   Net earnings / employee   112 137 0 361 70 86 0 0